Weisman Gary A, Yu Ningpu, Liao Zhongji, Gonzaléz Fernando, Erb Laurie, Seye Cheikh I
Department of Biochemistry, 540 Life Sciences Center, University of Missouri-Columbia, Columbia, MO 65211, USA.
Biotechnol Genet Eng Rev. 2006;22:171-95. doi: 10.1080/02648725.2006.10648070.
In the past ten years since the discovery and cloning of members of the P2 receptor family, rapid progress has been made in the field regarding the function and pharmacology of different P2 receptor subtypes. This research resulted in identifying these receptors as important players in the pathology of atherosclerosis, cystic fibrosis, neurodegenerative and autoimmune diseases, among other disorders. The signalling mechanisms whereby P2 receptors mediate pathogenesis are not clear in most cases. Future studies in this field will focus on the integration of signalling pathways coupled to P2 receptors and the generation of specific agonists/antagonists for each receptor subtype to provide strategies for the treatment of a variety of diseases.
自P2受体家族成员被发现和克隆以来的十年间，在不同P2受体亚型的功能和药理学领域取得了迅速进展。这项研究确定这些受体是动脉粥样硬化、囊性纤维化、神经退行性疾病和自身免疫性疾病等多种疾病病理学中的重要参与者。在大多数情况下，P2受体介导发病机制的信号传导机制尚不清楚。该领域未来的研究将集中于与P2受体偶联的信号通路整合以及为每种受体亚型生成特异性激动剂/拮抗剂，以提供治疗多种疾病的策略。
